✦ LIBER ✦

Phase I study of oral JM216 given twice daily

✍ Scribed by P. Beale; F. Raynaud; J. Hanwell; C. Berry; S. Moore; D. Odell; I. Judson

Publisher: Springer
Year: 1998
Tongue: English
Weight: 303 KB
Volume: 42
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800050797

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I study of oral uracil/ftorafur

A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days

✍ Mark D. DeMario; Mark J. Ratain; Nicholas J. Vogelzang; Sridhar Mani; Everett E. 📂 Article 📅 1999 🏛 Springer 🌐 English ⚖ 72 KB

Phase I study of an oral formulation of

Phase I study of an oral formulation of irinotecan administered daily for 14

✍ Nadja E. Schoemaker; I. E. L. M. Kuppens; Wim W. Ten Bokkel Huinink; Patricia Le 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 227 KB

A phase I and pharmacokinetic study of a

A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5

✍ Henry C. Pitot; Alex A. Adjei; Joel M. Reid; Jeff A. Sloan; Pamela J. Atherton; 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 296 KB

Treatment of myelodysplastic syndromes w

Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I–II study

✍ Bernard R. Greenberg; Ralph D. Reynolds; Carolyn B. Charron; Kathleen M. Squilla 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 375 KB 👁 2 views

A phase 2 study of a fixed combination o

A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer

✍ Gabriel N. Hortobagyi; Robyn R. Young; Mark Karwal; Nuhad K. Ibrahim; Robert Her 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 1 views

Phase I study of oral spirogermanium

✍ Jimmie Harvey; Molly McFadden; Frederick P. Smith; Lucien Joubert; Philip S. Sch 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 241 KB

Thirty-three patients with advanced malignancy were treated with oral spirogermanium in a Phase I study to determine a maximum tolerated dose. Patients were entered in the study at doses of 100, 200, and 300 milligrams daily. The dose-limiting toxicity was gastrointestinal with moderate nausea and v